CymaBay Therapeutics Inc (NASDAQ:CBAY) has been given a consensus rating of “Buy” by the twelve ratings firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $21.75.
A number of analysts have recently commented on the company. Oppenheimer set a $18.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald set a $17.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, November 5th. BidaskClub raised CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 2nd. Finally, Piper Jaffray Companies lifted their price target on CymaBay Therapeutics to $30.00 and gave the company an “overweight” rating in a research note on Friday, August 10th.
CymaBay Therapeutics stock opened at $11.56 on Wednesday. CymaBay Therapeutics has a 12-month low of $7.63 and a 12-month high of $15.59. The stock has a market capitalization of $693.66 million, a price-to-earnings ratio of -14.63 and a beta of 1.89.
CymaBay Therapeutics (NASDAQ:CBAY) last released its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04). On average, equities research analysts forecast that CymaBay Therapeutics will post -1.23 EPS for the current year.
In related news, VP Daniel Menold sold 5,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Wednesday, August 29th. The stock was sold at an average price of $13.00, for a total value of $65,000.00. Following the transaction, the vice president now directly owns 5,000 shares of the company’s stock, valued at $65,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.50% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc acquired a new position in shares of CymaBay Therapeutics in the second quarter worth approximately $134,000. LPL Financial LLC acquired a new position in shares of CymaBay Therapeutics in the first quarter worth approximately $130,000. State Board of Administration of Florida Retirement System acquired a new position in shares of CymaBay Therapeutics in the second quarter worth approximately $145,000. Teacher Retirement System of Texas acquired a new position in shares of CymaBay Therapeutics in the second quarter worth approximately $151,000. Finally, PNC Financial Services Group Inc. acquired a new position in shares of CymaBay Therapeutics in the second quarter worth approximately $152,000. 95.69% of the stock is currently owned by institutional investors.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: Hedge Funds
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.